Plasma Renin Activity Is an Independent Prognosticator in Patients With Myocardial Infarction.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
24 05 2019
Historique:
pubmed: 23 4 2019
medline: 23 7 2020
entrez: 23 4 2019
Statut: ppublish

Résumé

Plasma renin activity (PRA) is associated with cardiovascular events in patients with heart failure (HF), but its prognostic role in acute myocardial infarction (AMI) is unclear.Methods and Results:A total of 878 patients with information on baseline PRA on admission were selected from 1,055 AMI patients who underwent emergency coronary angiography between 2007 and 2016. The patients were divided into 2 groups according to their median PRA (2.0 ng/mL/h). The primary endpoint was major adverse cardiac events (MACE), defined as a composite of cardiovascular death and hospitalization because of HF. During follow-up (median 4.5±3.1 years), MACE occurred in 108 patients. Kaplan-Meier analysis showed that the high PRA group had significantly lower MACE-free survival than the low PRA group (log-rank P=0.0009). By multivariate analysis, high PRA was an independent predictor of MACE (hazard ratio (HR) 1.573; 95% confidence interval (CI) 1.049-2.396, P=0.0282). Similarly, among 580 patients who had not been previously treated with renin-angiotensin system inhibitors or β-blockers on admission, high PRA was an independent predictor of MACE (HR 1.732; 95% CI 1.010-3.047, P=0.0460). In the studied AMI patients, elevated levels of PRA were independently associated with poor prognosis.

Sections du résumé

BACKGROUND
Plasma renin activity (PRA) is associated with cardiovascular events in patients with heart failure (HF), but its prognostic role in acute myocardial infarction (AMI) is unclear.Methods and Results:A total of 878 patients with information on baseline PRA on admission were selected from 1,055 AMI patients who underwent emergency coronary angiography between 2007 and 2016. The patients were divided into 2 groups according to their median PRA (2.0 ng/mL/h). The primary endpoint was major adverse cardiac events (MACE), defined as a composite of cardiovascular death and hospitalization because of HF. During follow-up (median 4.5±3.1 years), MACE occurred in 108 patients. Kaplan-Meier analysis showed that the high PRA group had significantly lower MACE-free survival than the low PRA group (log-rank P=0.0009). By multivariate analysis, high PRA was an independent predictor of MACE (hazard ratio (HR) 1.573; 95% confidence interval (CI) 1.049-2.396, P=0.0282). Similarly, among 580 patients who had not been previously treated with renin-angiotensin system inhibitors or β-blockers on admission, high PRA was an independent predictor of MACE (HR 1.732; 95% CI 1.010-3.047, P=0.0460).
CONCLUSIONS
In the studied AMI patients, elevated levels of PRA were independently associated with poor prognosis.

Identifiants

pubmed: 31006732
doi: 10.1253/circj.CJ-18-1195
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Renin EC 3.4.23.15

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1324-1329

Commentaires et corrections

Type : CommentIn

Auteurs

Daisuke Kamon (D)

Department of Cardiovascular Medicine, Nara Medical University.

Hiroyuki Okura (H)

Department of Cardiovascular Medicine, Nara Medical University.

Akihiko Okamura (A)

Department of Cardiovascular Medicine, Nara Medical University.

Yasuki Nakada (Y)

Department of Cardiovascular Medicine, Nara Medical University.

Yukihiro Hashimoto (Y)

Department of Cardiovascular Medicine, Nara Medical University.

Yu Sugawara (Y)

Department of Cardiovascular Medicine, Nara Medical University.

Tomoya Ueda (T)

Department of Cardiovascular Medicine, Nara Medical University.

Taku Nishida (T)

Department of Cardiovascular Medicine, Nara Medical University.

Kenji Onoue (K)

Department of Cardiovascular Medicine, Nara Medical University.

Tsunenari Soeda (T)

Department of Cardiovascular Medicine, Nara Medical University.

Satoshi Okayama (S)

Department of Cardiovascular Medicine, Nara Medical University.

Makoto Watanabe (M)

Department of Cardiovascular Medicine, Nara Medical University.

Rika Kawakami (R)

Department of Cardiovascular Medicine, Nara Medical University.

Yoshihiko Saito (Y)

Department of Cardiovascular Medicine, Nara Medical University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH